CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 1 enrolled
Drug / intervention
diltiazemdrug
Likely dose
diltiazem 0.25 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06534671
NCT06534671Phase 4Completed
CompareCT.gov

Diltiazem in Jervell and Lange-Nielsen Syndrome

Vanderbilt University Medical Center·interventional·Posted Aug 2, 2024·Updated Oct 14, 2025

In Brief

A Phase 4 clinical trial evaluating diltiazem for Jervell and Lange Nielsen Syndrome. Completed, enrolled 1 participant across 1 site.

Detailed Summary

This study will test the effect of diltiazem, a calcium channel blocking drug, on the QT interval in patients with Jervell and Lange-Nielsen syndrome. This will be a single IV dose and acute effects (within minutes) will be observed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsJervell and Lange Nielsen Syndrome
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20252026
First PostedAug 2, 2024
Enrollment StartOct 16, 2024
Primary CompletionOct 23, 2024
TodayJul 2, 2026
Enrollment to primary: 7 daysPosted 1.9 years ago

Interventions

diltiazemdrug

IV diltiazem (0.25 mg/kg) will be given over 2 minutes, with ECG and blood pressure measurements at baseline, 2, 5, 7, 10, 15 and 20 minutes. If at 10 minutes there is no QT shortening, and blood pressure is stable, an additional dose (0.35 mg/kg) will be given with ECG and blood pressure measurements at 17, 20, 22, 25, 30 and 35 minutes.